Homeodomain-interacting protein kinase 2 (HIPK2) is an emerging player in cell response to genotoxic agents that senses damage intensity and contributes to the cell's choice between cell cycle arrest and apoptosis. Phosphorylation of p53 at S46, an apoptosis-specific p53 posttranslational modification, is the most characterized HIPK2 function in response to lethal doses of ultraviolet (UV), ionizing radiation or different anticancer drugs, such as cisplatin, roscovitine and doxorubicin (DOX). Indeed, like p53, HIPK2 has been shown to contribute to the effectiveness of these treatments. Interestingly, p53-independent mechanisms of HIPK2-induced apoptosis were described for UV and tumor growth factor-b treatments; however, it is unknown whether these mechanisms are relevant for the responses to anticancer drugs. Because of the importance of the so-called 'p53-independent apoptosis and drug response' in human cancer chemotherapy, we asked whether p53-independent factor(s) might be involved in HIPK2-mediated chemosensitivity. Here, we show that HIPK2 depletion by RNA interference induces resistance to different anticancer drugs even in p53-null cells, suggesting the involvement of HIPK2 targets other than p53 in response to chemotherapy. In particular, we found that HIPK2 phosphorylates and promotes proteasomal degradation of DNp63a, a prosurvival DN isoform of the p53 family member, p63. Indeed, effective cell response to different genotoxic agents was shown to require phosphorylation-induced proteasomal degradation of DNp63a. In DOX-treated cells, we show that HIPK2 depletion interferes with DNp63a degradation, and expression of a HIPK2-resistant DNp63a-D390 mutant induces chemoresistance. We identify T397 as the DNp63a residue phosphorylated by HIPK2, and show that the nonphosphorylatable DNp63a-T397A mutant is not degraded in the face of either HIPK2 overexpression or DOX treatment. These results indicate DNp63a as a novel target of HIPK2 in response to genotoxic drugs.
Introduction
Homeodomain-interacting protein kinase 2 (HIPK2) is an evolutionarily conserved Serine/Threonine kinase, originally identified as co-repressor for homeodomain transcription factors (Kim et al., 1998) . HIPK2 interacts and phosphorylates at specific S/T residues, a still enlarging body of targets, involved in the regulation of gene transcription during development and in cell response to several types of stress (Calzado et al., 2007; Rinaldo et al., 2007b; Calzado et al., 2009 ). In the latter condition, HIPK2 is activated by different genotoxic stimuli, including ultraviolet (UV) (D'Orazi et al., 2002; Hofmann et al., 2002) , ionizing irradiation (Dauth et al., 2007) and anticancer drugs such as cisplatin (CDDP) (Di Stefano et al., 2004) , doxorubicin (DOX) (Rinaldo et al., 2007a) and roscovitine (Wesierska-Gadek et al., 2007) . Depletion of HIPK2 expression by specific antisense oligonucleotides or interfering RNAs induces strong resistance to the apoptosis caused by these agents, supporting a functional role by the kinase in response to these stresses.
A few mechanisms of HIPK2 inactivation in human cancers have been identified, such as HIPK2-forced cytoplasmic relocalization in breast carcinomas and in leukemogenesis (Pierantoni et al., 2007; Wee et al., 2008) , HIPK2 mutations in acute myeloid leukemia (Li et al., 2007) and loss of HIPK2 protein expression and allele-specific loss-of-heterozygosity in thyroid cancers (Lavra et al., 2011) . At least in the case of breast cancer biopsies, HIPK2 inactivation was significantly associated with overexpression of the prosurvival a 6 b 4 integrin (Bon et al., 2009) and with tumor resistance to spontaneous apoptosis (Pierantoni et al., 2007) .
The tumor suppressor p53, a key mediator of DNA damage response (DDR) and a critical player in the maintenance of genomic stability, has been the first identified HIPK2 target involved in DDR. HIPK2 was shown to bind p53 and differentially regulate its localization, phosphorylation, acetylation and transcriptional activity, depending on the extent of the damage. In particular, upon severe, presumably irreparable DNA damage induced by lethal doses of UV, CDDP or DOX, HIPK2 is strongly upregulated and phosphorylates human p53 at S46 (Puca et al., 2010) , an apoptosisspecific p53 posttranslational modification (Oda et al., 2000) or its mouse ortholog at S58 (Cecchinelli et al., 2006b) . In contrast, in less severe, presumably reparable DNA damage conditions induced by sub-lethal doses of UV or DOX, HIPK2 is ubiquitylated by MDM2 in a p53 dependent manner and targeted to proteasomal degradation (Rinaldo et al., 2007a) . These findings identify HIPK2 as a critical target for the p53/MDM2 pathway in the cell decision between cell cycle arrest and apoptosis during DDR, and further support the hypothesis that HIPK2 contributes to tumor cell responsiveness to anticancer treatments.
Besides p53 phosphorylation, HIPK2 promotes apoptosis by modulating other factors, directly or indirectly related to p53-mediated apoptosis, such as the b-catenin regulator Axin, the p53 family member p73, the p53 inhibitor MDM2, the acetyl transferases p300/CPB and PCaF (Rinaldo et al., 2007b; Li et al., 2009; Puca et al., 2010) , and, more recently, PML (Gresko et al., 2009 ) and the methyl-CpG-binding protein 2 (Bracaglia et al., 2009 ). In addition, HIPK2 depletion in human tumor cells was shown to induce p53 misfolding, yielding a 'mutant-like' p53 conformation and resistance to DOX and CDDP (Puca et al., 2008) .
Interestingly, p53-independent functions of HIPK2 were also identified in UV and tumor growth factor-b-induced apoptosis. In p53-deficient cells, UV-activated HIPK2 phosphorylates the transcriptional co-repressor CtBP at S422 and targets it for proteasomal degradation (Zhang et al., 2003) . Again, in p53-deficient cells, HIPK2 participates in the tumor growth factor-b-induced apoptosis, leading to activation of the stress-stimulated kinase, c-Jun NH(2)-Terminal Kinase (JNK) (Hofmann et al., 2003) . Although these events are not confined to p53-deficient cells and the experiments have been performed only upon induction of apoptosis by UV irradiation or tumor growth factor-b-treatment, these results suggest that HIPK2 might contribute to tumor chemosensitivity, even in the absence of wild type (wt) p53. Because of the relevance for human cancer treatments of p53-independent components in apoptosis and drug response (Leong et al., 2007; Vilgelm et al., 2008) , we asked whether p53-independent factor(s) might be involved in the HIPK2-mediated response to chemotherapy.
In this study, we have shown that HIPK2 is stabilized upon treatment with different drugs independently from the TP53 gene status, and that, HIPK2 depletion by RNA interference induces chemoresistance even in p53-defective cells. Looking for p53-independent HIPK2 targets in these conditions, we found that the prosurvival factor DNp63a is directly phosphorylated by HIPK2 at T397, and this kinase activity is required for the DNp63a degradation in response to anticancer therapy.
Results

HIPK2 contributes to tumor cell chemosensitivity through p53-dependent and -independent mechanisms
To analyze the role of HIPK2 in response to different anticancer drugs, we first performed time course analyses of HIPK2 expression in wtp53-carrying RKO cells upon treatment with previously defined, apoptotic doses of etoposide, DOX or bleomycin, whereas UV irradiation was used as positive control. As shown in Figure 1a , a time-dependent increase of HIPK2 levels was observed with each drug. Then, we verify whether HIPK2 has a causal role in the cell response to these different drugs by employing two stable polyclonal populations of HIPK2-interfered RKO cells (HIPK2i-1 and HIPK2i-2), obtained by transfection of two different HIPK2-specific interfering sequences (see Materials and methods; Figure 1b , insert panel). Colony Figure 1 HIPK2 is involved in tumor cell response to antineoplastic drugs. RKO cells were treated with etoposide (EPEG), DOX or bleomycin (BLM) at the indicated doses. UV radiation at 50 J/m 2 was used as positive control for HIPK2 protein stabilization. (a) TCEs were prepared at the indicated times after treatment (h) and analyzed by western blot (WB) for HIPK2 protein expression. Tubulin expression shows equal loading of samples. (b) RKO cells were stably depleted for HIPK2 by two different shRNAs. HIPK2 depletion was verified by WB analysis (small insert). Interfered cells (HIPK2i-1 and HIPK2i-2) and control cells (Ctr-i) were treated with the indicated drugs as in (a) and plated for colony forming assay 24 h post-treatment. Columns are average of three independent experiments and bars indicate standard deviation. Student's t-test: ***Po0.0001.
HIPK2/DNp63a axis in DNA damage response C Lazzari et al formation assays showed that, compared with controlinterfered (Ctr-i) cells, both RKO-HIPK2i populations have an increased resistance to all tested drugs, further supporting the rising idea that HIPK2 is involved in the cell response to a wide range of stresses.
As HIPK2 was shown to induce apoptosis in p53-dependent and -independent manners, we tested the same drugs on p53-null cells in the presence or absence of HIPK2 depletion. As shown in Figure 2a , HIPK2 upregulation was induced in p53-null H1299 cells, and the resistance of these cells to etoposide and bleomycin was strongly increased in two stable HIPK2i populations obtained as for RKO cells (Figure 2b ), indicating the involvement of p53-independent mechanism(s). We were not able to measure any colony forming capacity of our H1299 cells upon DOX treatment, even at doses as low as 20 nM (data not shown); thus, to test the HIPK2/ p53 dependency to this drug, we employed the HCT116 isogenic cell model consisting of wtp53-carrying parental cells and their p53-null derivatives (Bunz et al., 1998) . To avoid selection differences between the two populations promoted by stable transfection, HIPK2 depletion in the p53-proficient and -defective HCT116 cells was induced upon transient transfection of specific Stealth RNA duplex (see Materials and methods) and quantified by real-time reverse transcription PCR ( Figure 2c ). As expected, in the Ctr-depleted cells (universal negative control), reduction in DOX-induced apoptosis was observed in the p53-null population, compared with the p53-proficient one (Figures 2d and e , compare the black columns). Still, a further reduction in DOX-induced apoptosis was observed in both populations upon HIPK2 depletion (Figures 2d and e) , further supporting the existence of HIPK2-mediated, p53-independent mechanism(s) of chemoresponse.
HIPK2 contributes to DNp63a degradation in response to DOX, independently of the TP53 gene status It has been shown that HIPK2 interacts with the other members of the p53 family, p73 and p63; however, the functional role(s) of these interactions are still mainly unknown (Kim et al., 2002) . In the past few years, several studies have revealed that apoptotic doses of UV irradiation or genotoxic drugs promote a phosphorylation-induced, proteasome-mediated degradation of the prosurvival isoform DNp63a and a subsequent modification of its transcriptional activity (Liefer et al., 2000; Papoutsaki et al., 2005; Westfall et al., 2005; Zangen et al., 2005; Muller et al., 2006) . Thus, we asked whether DNp63a, that was already shown to be bound by HIPK2 (Kim et al., 2002) , might be one of the HIPK2 targets in DDR. To begin assessing this idea, we first confirmed the binding between the two proteins (Supplementary Figure 1a) . Next, we tested HIPK2 expression in the presence or absence of apoptotic doses of DOX in three different cell lines, MCF-10A, HaCat and FaDu, known to express detectable levels of endogenous DNp63a (Ciardiello et al., 1990; Li et al., 2008) , as we also confirmed by isoform-specific RT-PCR analysis (Du et al., 2010 ; data not shown). RKO were used as Ctr from the previous experiments ( Figure 1 ). As shown in Figure 3a , HIPK2 expression increased upon DOX treatment, independently of the TP53 gene status, that is, wt in the MCF-10A and mutated in HaCat and FaDu cells. As expected, DOX treatment stabilized p53 only in the wtp53-carrying cells, whereas it strongly reduced DNp63a expression (Figures 3b-d ) in all cells, supporting its independency from p53, as previously reported (Fomenkov et al., 2004) . To evaluate whether the DOX-induced repression of DNp63a. This partial rescue of DNp63a expression induced by HIPK2 depletion was also associated with a reduced inhibition of a few DNp63a transcription target genes, already shown to be modulated by CDDPtreatment (Huang et al., 2010) . After assessing the modulation of c-JUN, CDH1, CARM and EGFR in CDDP-and DOX-treated FaDu cells by real-time Figure 1b) , we measured their expression in Ctr and HIPK2-depleted cells, observing a partial recovery in the latter ones (Figure 3g ).To evaluate more directly whether HIPK2 reduces DNp63a protein expression by degradation, as described for genotoxic treatments, increasing amount of EGFP-tagged HIPK2 was transfected in FaDu cells in the absence or presence of the proteasomal inhibitor MG132. Western blot analyses of total cell extracts (TCEs) showed a reduction of the endogenous DNp63a protein levels (Figures 3h and i) that was rescued by the addition of MG132 (Figure 3i ), indicating that HIPK2 can promote DNp63a degradation. In agreement, a reduced half-life of the endogenous DNp63a protein was observed upon HIPK2 overexpression and cyclohexamide treatment (Figure 3j ).
The C-terminal region of DNp63a is required for its HIPK2-induced degradation HIPK2 was previously shown to bind p63 in its Cterminal region (Kim et al., 2002 ); thus, we tested whether a C-terminal deletion mutant of DNp63a, the D390 that encodes for a protein deleted from amino-acid 390 to the stop codon of the human DNp63a (5c) and is not phosphorylated upon UV (Papoutsaki et al., 2005) , was still degraded by HIPK2 overexpression or DOX treatment. Western blot analyses of FaDu cells cotransfected with EGFP-HIPK2 and Myc-tagged DNp63a or D390 showed that only the full-length DNp63a expression is repressed (Figure 4a ). Similar results were obtained upon DOX treatment of FaDu, HaCat and H1299 cells transfected with Myc-DNp63a or Myc-D390-deletion mutant (Figure 4b ). Taken together, these results indicate that the C-terminal region of DNp63a is required for its DOX-induced, HIPK2-mediated degradation. As DNp63a degradation is required for effective cellular response to genotoxic drugs (Liefer et al., 2000; Huang et al., 2008) , we asked whether overexpression of the D390-deletion mutant might induce resistance to DOX. Colony formation assays were performed on FaDu cells upon transfection with DNp63a or D390 and DOX treatment. As expected, both proteins increased the colony formation efficiency compared with the Ctr vector-transfected cells, but D390 was more efficient than wt-DNp63a (Figure 4c ), supporting the concept that the C-terminal region of DNp63a is required for cell sensitivity to DOX.
HIPK2 phosphorylates DNp63a at T397 and this kinase activity is required for DNp63a degradation HIPK2 regulates several of its targets through the S/T kinase activity (Rinaldo et al., 2007b) . Thus, we first asked whether HIPK2 directly phosphorylates p63 in an in vitro kinase assay. Comparable amounts of eukaryotic GST-HIPK2 (eGST-HIPK2) and of its kinasedead K221R mutant (eGST-K221R) were produced in (Cecchinelli et al., 2006b) . As shown in Figure 5a , wt-HIPK2, but not the kinase-dead mutant, was able to phosphorylate itself and p63, indicating that HIPK2 phosphorylates p63 in vitro.
Next, we assessed whether the HIPK2 kinase activity is required for DNp63a degradation. FaDu cells were transfected with EGFP-HIPK2, EGFP-K221R kinasedead mutant or EGFP alone, and TCEs analyzed by western blot for the endogenous DNp63a protein levels. Also in this case, only wt-HIPK2 was able to reduce DNp63a expression (Figure 5b) , suggesting that the kinase activity of HIPK2 is required for DNp63a degradation.
A strong functional link between DNp63a phosphorylation and its subsequent degradation has been observed upon treatment with different genotoxic agents (Papoutsaki et al., 2005; Westfall et al., 2005; Huang et al., 2008; Galli et al., 2010) . In addition, upon CDDP treatment, three specific phosphorylation sites (that is, S375, T397 and S466) have been identified in the C-terminal region of DNp63a by mass spectrometry (Huang et al., 2008;  Figure 5c , underscored sites). Interestingly, one of these sites, the T397, belongs to the recognition motif usually phosphorylated by HIPK2, that is, S or T, followed or preceded by P. Thus, although there are 10 such motifs in the Cterminal region of DNp63a (Figure 5c , big bold residues), we first tested whether HIPK2 phosphorylates DNp63a at T397. In vitro kinase assay was performed by incubating comparable amounts of bacterially-produced proteins (wt-GST-DNp63a or its non-phosphorylatable form at T397, the GST-T397A mutant; Figure 5d ), with commercially available active-HIPK2 (see Materials and methods), in the presence of [g 32 P]-ATP. A strong phosphorylation signal was observed only with the wt-GST-DNp63a protein (Figure 5e ), indicating that HIPK2 phosphorylates DNp63a at the T397 site.
Inhibition of DNp63a phosphorylation at T397 upon CDDP treatment was shown to interfere with DNp63a degradation (Huang et al., 2008) . Thus, to confirm that the DOX-induced, HIPK2-mediated degradation of DNp63a depends on T397 phosphorylation, cells were co-transfected with EGFP-HIPK2 and wt-Myc-DNp63a, or the non-phosphorylatable Myc-T397A mutant. As shown in Figures 5f and g, the T397A mutant was resistant to HIPK2-induced degradation and as a longer half-life than the wt-DNp63a, as measured by cyclohexamide treatment. Comparable results were obtained in FaDu cells upon transfection with the same Myc-DNp63a or Myc-T397A expressing vectors and treated with DOX. Indeed, we observed that the T397A mutant (i) is more resistant to DOX-induced DNp63a repression (Figure 5h , left panel), (ii) inhibits cell death (Figure 5h , right panel) and (iii) is less ubiquitylated than the wt form (Figure 5i ), indicating that in cell response to DOX, HIPK2 contributes to DNp63a degradation by its phosphorylation at T397.
Discussion
In this study, we investigated whether the p53 proapoptotic activator HIPK2 contributes to the cellular response to chemotherapy through molecular mechanism(s) other than those mediated by p53. We show that the DOX-induced degradation of the prosurvival factor DNp63a is induced by HIPK2 in a p53-independent manner. In particular, HIPK2 depletion by RNA interference was sufficient to inhibit drug-induced DNp63a degradation even in mutant p53-carrying cells. Furthermore, we found that HIPK2 phosphorylates DNp63a at T397, and this specific posttranslational modification strongly contributes to both HIPK2-and DOX-induced degradation of DNp63a and susceptibility to DOX. In addition, we showed that a C-terminal deletion mutant of DNp63a missing the T397 site, the D390 mutant, strongly increase cell resistance to DOX.
DNp63a is one of the N-terminal-defective isoforms encoded by the TP63 gene. Transcription of TP63 can be initiated at two alternative transcription start sites, resulting in the transcription-activating (TA) p63 and DNp63 isoforms that contain or lack, respectively, a TA domain (Yang et al., 1998) . The DNp63 isoforms possess dominant-inhibitory functions over the TA isoforms of the p53 family (TAp63, TAp73 and p53) that usually result in prosurvival and pro-proliferation activities (Parsa et al., 1999; Barbieri et al., 2005; Wu et al., 2005; Rocco et al., 2006) . Overexpression of DNp63 has been frequently observed in squamous cell carcinoma and in some other epithelial tumors (Hibi et al., 2000; Senoo et al., 2001; Moll and Slade, 2004; Lin et al., 2006) and, beyond its dominant negative effect over the pro-apoptotic and growth-arresting functions of the TA isoforms, DNp63 was found to contribute to tumor progression by favoring angiogenesis and chemoresistance (Wu et al., 2005; Zangen et al., 2005; Lanza et al., 2006; Muller et al., 2006; Rocco et al., 2006) and by modulating cell adhesion processes (Carroll et al., 2006; Yang et al., 2006) . Regardless of the HIPK2-mediated regulation of DNp63a in response to DOX, we observed that HIPK2 depletion results in an increased expression of DNp63a even in non-stressing conditions (Figure 3e and data not shown), suggesting that the tumorassociated HIPK2 inactivation might contribute to DNp63a overexpression. We previously found a similar behavior for the prosurvival factor galectin-3, whose expression is strongly increased in several human cancers, at least in part, because of the lack of a HIPK2-dependent, p53-mediated repression of Galectin-3 transcription (Cecchinelli et al., 2006a; Lavra et al., submitted) . In this regard, it will be interesting to evaluate DNp63a expression in those human tumors in which HIPK2 has been found inactive. To this aim, we have started to analyze, by immunohistochemistry for HIPK2 and p63 staining, 20 thyroid cancers and six benign thyroid hyperplasia. As shown in Table 1 , a strong inverse correlation between the two proteins was observed, supporting the idea that the tumor-associated reduction of HIPK2 expression is compatible with the induction of p63 expression.
HIPK2/DNp63a axis in DNA damage response C Lazzari et al Increasing evidence indicates that regulation of protein stability is a key mechanism to control p63 isoforms' actions through different E3-ubiquitin ligases (Muller et al., 2006) . Thus far, we found that neither Itch nor MDM2 are responsible for the HIPK2-induced degradation of DNp63a (Supplementary Figures 1c   and d) . In response to several genotoxic agents, ubiquitylation and proteasomal degradation were shown to be prevented by phosphorylation on the TA isoforms (Rossi et al., 2006; Li et al., 2008; MacPartlin et al., 2008) , whereas promoted also, by phosphorylation on the DN isoforms (Liefer et al., 2000; Westfall et al., 2005;  HIPK2/DNp63a axis in DNA damage response C Lazzari et al Zangen et al., 2005) . Though Y phosphorylation was overall shown to be associated to TA stability (Gonfloni et al., 2009; Wang et al., 2010) and S/T phosphorylation to DN degradation (Westfall et al., 2005; Huang et al., 2008; Galli et al., 2010) , the molecular pathways underlying these divergent events and their balance have just begun to be described. The HIPK2 activity on DNp63a we are reporting here is consistent with the general idea that the cellular amount of this p63 isoform has to be reduced to enable an effective DDR. A phosphorylation-dependent prodegradation function of HIPK2 has already been reported for CtBP, c-Myb and ZBTB4 (Zhang et al., 2003; Kanei-Ishii et al., 2004; Yamada et al., 2009) , suggesting that it might be a common mechanism to destabilize prosurvival factors. Puzzling, the HIPK2 kinase activity is required for the apoptosis-specific activation of p53. How the same kinase drives molecules, even from the same family, such as p53 and DNp63a to so divergent fates is presently unidentified. We know that p53 is phosphorylated by HIPK2 in its N-terminus and this homologous region in DNp63a is absent. On the opposite site, HIPK2 phosphorylates DNp63a at the C-terminus in the SAM domain, a region absent in p53 (Irwin and Kaelin, 2001 ).
On the basis of these data, one might speculate that HIPK2 phosphorylation at the N-or C-terminus promotes activation or degradation, respectively. However, too little information is available thus far to make a model. It will be interesting to verify, for example, whether the described HIPK2 cooperation activity with TAp73 depends on its HIPK2-induced phosphorylation at the N-terminus, or whether p53 can be the only member of the family activated by direct HIPK2-induced phosphorylation because, at variance from the p63 and p73 isoforms, it is not phosphorylated at Y residues. HIPK2 phosphorylates DNp63a at T397, one of the three residues previously identified by mass spectrometry, as phosphorylation sites targeted in response to CDDP treatment (that is, S385, T397, S466 ; Huang et al., 2008) . On the basis of the kinase recognition motifs, the authors proposed that the three sites are phosphorylated by ATM, CDK2 and p70s6 K, respectively. Although specific RNA interference for ATM and p70s6 K significantly reduced phosphorylation of their relative sites, CDK2 depletion or inactivation only marginally reduced CDDP-induced DNp63a degrada- Table 1 Immunohistochemistry of HIPK2 and p63 in thyroid
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Abbreviation: HIPK2, homeodomain-interacting protein kinase 2. HIPK2/DNp63a axis in DNA damage response C Lazzari et al tion, suggesting that other kinases recognizing the same motif might be also involved. Interestingly, Huang and collaborators (2008) elegantly showed by Flp-In technology in HNSCC 029 cells, the requirement of each of these sites in the CDDP-induced degradation of DNp63a. Our data are consistent with these results, as we found that the T397A mutant is completely resistant to DOX-and HIPK2-induced degradation, indicating that at least this phosphorylation site is involved in cell response to both CDDP and DOX. In addition, the authors showed a time-dependent hierarchy in the phosphorylation sites, with S385, an ATM target, being the first to be phosphorylated upon CDDP and being required for the subsequent phosphorylation at the two other sites. This observation is also very intriguing in view of our results, because ATM is also involved in HIPK2 activation (Dauth et al., 2007; Winter et al., 2008) , as well as in p53 phosphorylation at S15, a posttranslational modification that precede S46 (Oda et al., 2000) . Taken together, these observations suggest that in DDR, the ATM sensor, among different functions, activates HIPK2 and prepares p53 and its antagonist DNp63a, to the subsequent HIPK2-induced phosphorylation that drives these molecules to their respective fates.
The HIPK2 destabilizing activity on DNp63a we described upon treatment with different anticancer drugs, independently from the TP53 gene status, further support the concept that HIPK2 contribute to DDR in p53-dependent and -independent manners. However, this observation does not exclude the possibility that both pathways are engaged simultaneously in cells that carry wtp53 and express DNp63a, such as the MCF10A cells we employed here. In this type of cells, druginduced activation of HIPK2 would (i) activate p53 by S46 phosphorylation, (ii) promote the degradation of DNp63a by T397 phosphorylation and (iii) further improve p53 activity by removing the dominant inhibitory effect by DNp63a (Figure 6 ). These data indicate that HIPK2 has a double commitment, working as activator for proapoptotic factors and inhibitor for antiapoptotic one. On the opposite site, these considerations would allow to suppose that tumor-associated inhibition of HIPK2 activity might strongly contribute to chemoresistance in addition to other better-characterized events, such as p53 mutation/inactivation or DNp63 overexpression. HIPK2-related data from human tumor samples are still insufficient to be significant. We hope that the enlarging body of experimental evidence supporting key roles for HIPK2 in tumorigenicity and drug response would encourage the development of more extensive translational studies.
Materials and methods
Cells culture conditions and treatments RKO, FaDu, HaCat, HCT116 p53 þ / þ and p53À/À (Bunz et al., 1998) , U2OS and p53-null mouse embryonic fibroblasts were cultured in Dulbecco's modified Eagle medium, supplemented with 10% heat-inactivated fetal bovine serum. Immortalized human mammary MCF-10A cells (Ciardiello et al., 1990) were cultured in mammary epithelium basal medium, supplemented with MEGM SingleQuots (Clonetics, Lonza Milano S.r.l., Milano, Italy). For drug treatment, subconfluent cells were incubated in the presence of DOX (Sigma, St Louis, MO, USA), bleomycin (Aventis Pharma, Varese, Italy), Etoposide (Bristol-Myers Squibb, Princeton, NJ, USA) or MG132 (Calbiochem, Gibbstown, NJ, USA), at the indicated concentrations.
Expression vectors and transfection
The following plasmids were employed: pCDNA3-Myc-DNp63a, pCDNA3-Myc-T397A and pCDNA3-Myc-D390 (Papoutsaki et al., 2005; Di Costanzo et al., 2009) ; pEGFP-HIPK2 and pEGFP-K221R (Cecchinelli et al., 2006b) ; pEGFP-C2 (Stratagene, Santa Clara, CA, USA). Plasmids pGex-DNp63a and pGexDNp63a(T397A) were obtained by PCR amplification from pCDNA3-Myc-DNp63a and pCDNA3-Myc-T397A using specific primers: DNp63 BamH-upper: 5 0 -CGATATG-GATCCTTGTACCTGGAAAA CAATGCCC-3 0 ; DNp63 Xho1-lower: 5 0 -CGTATACTCGAGTCATTCTCCTTCCTC TTTGATACG-3 0 and cloned into a BamH1/Xho1 digested pGex6p-2rbs vector. The expression vectors were transfected by using Lipofectamine Plus reagent (Invitrogen, Carlsbad, CA, USA), according to manufacturer's instructions.
Western blot analyses
TCEs were prepared in RIPA buffer (50 mM Tris-HCl pH 8, 300 mM NaCl, 1 mM EDTA, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulphate, 1% Nonidet P40, 1 mM EDTA), supplemented with protease-inhibitor mix (Roche, Indianapolis, IN, USA). TCEs were resolved on precast NuPAGE 4-12% gels (Invitrogen), transferred onto nitrocellulose membranes (Bio-Rad, Hercules, CA, USA) and analyzed with the following antibodies: rabbit anti-HIPK2 (kindly provided by M.L. Schmitz), rabbit anti-p53 (FL-393) and mouse anti-p63 Figure 6 Model summarizing HIPK2 activity on p53 and DNp63a in response to antineoplastic drugs. Colony forming assay Cells were treated with drugs at the indicated doses for 24 h, then plated at low density in 60 mm petridishes and grown for a week in the absence of drugs. Surviving colonies were fixed and stained with crystal violet (0.5% in methanol; Sigma) and air-dried.
RNA interference
Stable interference by shRNA was performed by transfection of pRetroSuper and two different pRetroSuper-HIPK2 vectors carrying HIPK2-1376 or HIPK2-789 sequences (Cecchinelli et al., 2006a) . After 24 h from transfection, stable polyclonal populations of Ctr and HIPK2-depleted cells (HIPK2i-1 and HIPK2i-2 carrying HIPK2-1376 and HIPK2-789 sequences, respectively) were obtained by selection with 2 mg/ml puromycin. Transient interference by siRNA was obtained by HIPK2i Stealth RNAi sequences (a mix of three different sequences, transduced alone or in combination with comparable results) and universal negative control Stealth RNAi Negative, Medium GC Duplexes (Invitrogen). Cells were transduced by using the RNAiMAX reagent (Invitrogen), according to the manufacturer's instructions. In vitro kinase assay Recombinant eGST-HIPK2 and eGST-K221R were produced in H1299 cells by infection with the vaccinia virus vTF7-3 (kindly provided by Dr B Moss), followed by transfection with 2 mg of pcDNA3-eGST-HIPK2 or pcDNA3-eGST-K221R plasmids using Lipofectamine (Invitrogen) (Cecchinelli et al., 2006b) . TCEs were prepared 24 h post-transfection by incubation for 30 min at 4 1C in lysis buffer (50 mM Tris-HCl (pH 7.4), 300 mM NaCl, 150 mM KCl, 1 mM dithiothreitol, 1% Nonidet P-40). After centrifugation, eGST-fusion proteins were purified from supernatant by overnight incubation with glutathione-sepharose beads (Sigma) at 4 1C and used as enzymatic source. Alternatively, the active-HIPK2 fragment was purchased from Upstate and employed at the concentration of 50 ng/reaction. Recombinant GST-DNp63a and GST-T397A fusion proteins were produced in BL21 bacteria and purified on glutathione-sepharose resin (Sigma). For kinase assay, recombinant proteins were washed and incubated for 30 min at 30 1C in kinase buffer (20 mM Hepes (pH 7.4), 50 mM NaCl, 10 mM MgCl2, 10 mM MnCl2) in the presence of 185 KBq [g 32 P]-ATP. The phosphorylated substrates were resolved on precast NuPAGE 4-12% gels and analyzed by autoradiography.
Abbreviations CDDP, cisplatin; Ctr, control; DDR, DNA damage response; DOX, doxorubicin; eGST, eukaryotic-Glutathione S Transferase; HIPK2, homeodomain-interacting protein kinase 2; TCE, total cell extract.
